osteoporosis

in review 6 min read Updated 2026-11-19
osteoporosis

Osteoporosis Canada 2023 screens BMD by age + clinical risk factors (≥70 all; ≥65 with 1 CRF; 50–64 with fracture or ≥2 CRFs), uses Canadian FRAX (10-year MOF ≥20% = strong treat; 15–19.9% = conditional), and makes oral bisphosphonates first-line for 3–6 years. Never stop denosumab abruptly without bisphosphonate follow-on (rapid rebound vertebral fractures). For recent severe vertebral fracture (>40% height loss) or >1 vertebral fracture + T-score ≤−2.5, start an anabolic agent first then follow with an antiresorptive.


screening — OC 2023 vs CTFPHC 2023

Canadian guidelines diverge sharply on primary-prevention screening; specialty practice and Royal College exams follow Osteoporosis Canada 2023, while knowing CTFPHC’s position:

guidelinefemalesmalesmethod
Osteoporosis Canada 2023≥70: all · ≥65: ≥1 CRF · 50–64: fragility fracture or ≥2 CRFssame age + CRF criteria as femalestargeted BMD + Canadian FRAX (preferred over CAROC)
CTFPHC 2023 (primary prevention only)≥65: clinical FRAX first (no BMD) → BMD only if considering Rx · 40–64: strong against≥40: strong against screeningrisk-assessment–first (applies only to untreated patients without prior fragility fracture)
  • Clinical risk factors (CRFs): prior fragility fracture (>40 y), systemic glucocorticoids (>5 mg/day prednisone for >3 months in past year), ≥2 falls in past year, parental hip fracture, BMI <20 kg/m², smoking, alcohol ≥3 drinks/day, secondary osteoporosis (T1DM, hyperthyroidism, hypogonadism, malabsorption, RA, chronic liver disease).
  • Vertebral imaging (lateral spine X-ray or VFA): ~2/3 of vertebral fractures are clinically silent. Order if age ≥65 with T-score ≤−2.5, 10-year MOF risk 15–19.9%, or clinical clues (prospective height loss >2 cm, historical >6 cm, occiput-to-wall >5 cm, rib-to-pelvis ≤2 finger-breadths).
  • Premenopausal women & men <50: use Z-score (≤−2.0 = below expected range for age), not T-score.

treatment thresholds and secondary workup

when to treat (OC 2023)

  • Strong recommendation (high risk — treat without needing FRAX if fracture criteria met):
    • Prior hip, vertebral, or ≥2 osteoporosis-related fractures
    • 10-year MOF risk ≥20% (note: US BHOF also uses hip fracture ≥3%; OC 2023 uses MOF ≥20%)
    • Age ≥70 with T-score ≤−2.5 (femoral neck, total hip, or lumbar spine)
  • Conditional recommendation (moderate risk — shared decision-making, especially if recent fracture <2 y or recurrent falls):
    • 10-year MOF risk 15–19.9%
    • Age <70 with T-score ≤−2.5
  • Secondary-cause workup before starting therapy: calcium/albumin/PO₄, creatinine/eGFR, ALP, CBC, TSH, 25-OH vitamin D (if deficiency risk, malabsorption, or starting antiresorptive), SPEP if vertebral fracture; targeted PTH (if hypercalcaemic), tTG-IgA (coeliac), or morning testosterone (men).

pharmacotherapy choice, sequence, and duration

Full agent dosing, contraindications, and adverse effects → osteoporosis agents.

clinical scenariofirst-line choice (OC 2023)sequencing & duration
standard high/moderate riskoral bisphosphonate (alendronate or risedronate) — IV zoledronic acid if GI intolerance/adherence barriertreat 3–6 years (6 y if hip/vertebral/multiple fractures) → consider drug holiday if low/moderate residual risk; repeat BMD in 3 years
very high risk (recent <2 y severe vertebral fracture >40% height loss, OR >1 vertebral fracture + T-score ≤−2.5)anabolic first: romosozumab (12 months) or teriparatide (24 months)must transition to an antiresorptive immediately afterward to preserve BMD gains
bisphosphonate contraindicated / CrCl <30–35 / intolerantdenosumab 60 mg SC q6 months (not routine first-line)plan long-term uninterrupted therapy (never delay >1 month); re-evaluate at 6–10 years
postmenopausal <60 y or <10 y post-menopause with substantial vasomotor symptoms**[[menopause and hormone therapymenopausal hormone therapy]]**
intolerant to all above (low VTE risk)raloxifene 60 mg dailyvertebral fracture benefit only; increases VTE and hot flashes
denosumab discontinuation rebound

Unlike bisphosphonates, denosumab has no skeletal retention — stopping or delaying >1 month triggers rapid osteoclast rebound and multiple vertebral fractures. If stopped after ≤4 doses, transition to a bisphosphonate 6 months after the last injection for ≥1 year; if ≥5 doses, refer to an osteoporosis specialist for transition planning.

  • Inadequate response: >1 fracture or BMD decline ≥5% despite ≥1 year of adherent therapy → check adherence, falls, and secondary causes before extending or switching therapy.
  • Monitoring: repeat BMD 3 years after starting therapy or starting a bisphosphonate drug holiday (sooner if new fracture/steroids/secondary cause). If untreated: repeat BMD at 5–10 y (MOF <10%), 5 y (10–15%), or 3 y (>15%). Do not use FRAX/CAROC or bone turnover markers to monitor treatment response (OC 2023).
  • Non-pharmacologic (all patients): balance and functional training ≥2×/week (Grade A for falls) + progressive resistance training ≥2×/week (avoid rapid repetitive loaded spinal flexion/twisting); dietary calcium 1,000 mg/day (men 51–70) or 1,200 mg/day (women >50, men >70; avoid routine supplements if diet suffices); vitamin D 600 IU/day (51–70) / 800 IU/day (>70; Health Canada suggests ≥400 IU/day supplement); target 25-OH-D >75 nmol/L if deficient; Fracture Liaison Service after any fracture.

glucocorticoid-induced osteoporosis (ACR 2022)

Applies to adults starting or continuing ≥2.5 mg/day prednisone equivalent for >3 months (fracture risk rises rapidly within 3–6 months, primarily trabecular/vertebral).

  • Perform clinical fracture risk assessment + BMD + VFA/spine X-ray (plus GC-adjusted FRAX if ≥40 y) as soon as possible after starting steroids.
  • High/very high risk (prior osteoporotic fracture, T-score ≤−2.5, FRAX MOF ≥20% or hip ≥3%, or very high-dose steroids ≥30 mg/day for ≥30 days or cumulative ≥5 g/year) → start osteoporosis pharmacotherapy immediately (oral/IV bisphosphonate, denosumab, or PTH/PTHrP analogue [teriparatide] first in very high risk; ACR reserves romosozumab for intolerance of other agents given MI/stroke/death risk); moderate risk (≥40 y, MOF 10–19%, T-score −1.0 to −2.4) → treat with oral/IV bisphosphonate, denosumab, or PTH analogue.

paget disease of bone (ES 2014)

Focal accelerated osteoclastic bone resorption followed by disorganised osteoblastic remodelling (skull, pelvis, spine, femur, tibia).

  • Diagnosis: isolated elevated total ALP (or serum P1NP if abnormal LFTs — preferred over bone-specific ALP due to up to 20% cross-reactivity with liver ALP) + plain radiographs (thickened cortices, coarse trabeculae, osteolytic “blade of grass” lesions) → radionuclide bone scan once confirmed to map disease extent.
  • Indications to treat: symptomatic bone pain/deformity, active disease at high-risk sites (weight-bearing long bones, skull/hearing loss, spine/neurologic compression, adjacent to major joints), hypercalcaemia of immobilisation, or pre-operatively before surgery on pagetic bone (reduces intraoperative haemorrhage).
  • Treatment: single dose IV zoledronic acid 5 mg over 15 min is treatment of choice (induces multi-year biochemical remission; Ontario: ODB LU 319). Oral alternatives require higher daily dosing than osteoporosis: alendronate 40 mg/day × 6 months or risedronate 30 mg/day × 2 months. Follow total ALP (target below midpoint of reference range) rather than symptoms alone.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction osteoporosis